GC Biopharma Corp. (006280.KS), a South Korea-based biopharmaceutical company, announced on Monday that it has received Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for its intracerebroventricular (ICV) Enzyme Replacement Therapy (ERT) candidate, GC1130A, engineered for Sanfilippo Syndrome type A (mucopolysaccharidosis type IIIA), and produced in partnership with Novel Pharma.
GC1130A has previously achieved notable milestones by securing both Rare Pediatric Disease designation (RPDD) and Orphan Drug Designation (ODD) from the US FDA in January 2023. Building on these accomplishments, the latest approval in Europe adds another significant achievement.
Sanfilippo Syndrome (type A) is a genetic disorder that triggers central nervous system damage by accumulating Heparan sulphate, leading to a progressive neurodegeneration in paediatric population. Patients with MPS IIIA typically have a life expectancy of approximately 15 years, and as of now, there are no approved therapies available. In nonclinical studies, GC1130A demonstrated both safety and efficacy in eliminating Heparan sulphate and restoring brain function.
GC1130A has previously achieved notable milestones by securing both Rare Pediatric Disease designation (RPDD) and Orphan Drug Designation (ODD) from the US FDA in January 2023.
Argent BioPharma partners with SINTEF to advance chronic wound management
NRx Pharmaceuticals and HOPE Therapeutics align with FDA on Pediatric Study Plan for NRX-100
ToxStrategies acquires Clintrex Research
TPG invests in K2 Medical Research to expand clinical trial site platform
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Lipocine doses first cohort in LPCN 1154 study
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
AstraZeneca announces US approval for Ultomiris for NMOSD treatment
GenSight Biologics declares efficacy and safety of LUMEVOQ four years post-injection
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval